UNSPSC 51332805: Butaperazine maleate

This classification denotes an antipsychotic agent with the molecular formula C24H31N3OS.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22VUW43J2H, chemically known as 1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)-, dimaleate but generally known as butaperazine maleate, which bears US NIH Compound Identifier 6433234. European Medicines Agency schedules Butaperazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00913MIG.

UNSPSC 51332805 Butaperazine maleate is a Commodity code that nominally describes a specific antipsychotic pharmaceutical product, but recent state and local procurement activity under this code does not align with that narrow classification. The three recent opportunities solicited under the code—covering naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—indicate that state and local buyers are actually purchasing a broad range of pharmaceutical products and pharmacy benefit services rather than butaperazine maleate specifically. The mismatch suggests either that the code is being used as a catch-all placeholder for pharmaceutical procurements that do not fit narrower drug-specific codes, or that the opportunities have been tagged incorrectly. Issuing bodies include state health and human services agencies (Texas Health and Human Services Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent activity concentrates in Texas, Minnesota, and Florida. The Seminole County IFB (Solicitation IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county community health building; bidders must submit unit costs electronically and comply with E-Verify and drug-free workplace requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, with an April 3, 2026 response deadline) to gather market intelligence on direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing evaluation weighted 75 percent on competitiveness and awards effective July 1, 2026. Given the code's apparent misalignment with recent solicitations, the activity signals limited relevance for vendors specializing specifically in butaperazine maleate.